Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Завершено Фаза III Россия

CEP-10953 (Armodafinil)

A 12-Month, Open-Label, Flexible-Dosage (100 to 250 mg/Day) Study of the Safety and Efficacy of CEP-10953 in the Treatment of Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder (With an Open-Ended Extension Period)

Номер протоколаC10953/3023/ES/MN
ФазаФаза III
Участников по плану — во всех странах исследования328
Сроки01.01.2004 — 01.07.2006
Начало: 1 января 2004Окончание: 1 июля 2006
Плановый срок исследования истёк

Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00078312/

Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда

Простыми словами

Словарь терминов
  • Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
  • Исследование завершено, новых участников не набирают.
  • Возраст участников: 18–65 лет. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 328 чел. во всех странах исследования.
  • Центров в реестре: 8 в 2 городах. Список — ниже на странице.
  • Плановая дата окончания (07.2006) уже прошла.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возраст18–65 лет
ПолЛюбой
Здоровые добровольцынет
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 15 · невключение: 12

Критерии включения

  • Patients are included in the study if all of the following criteria are met:
  • Written informed consent is obtained.
  • Men and women (outpatients) of any ethnic origin, between 18 and 65 years of age (inclusive) are eligible.
  • The patient has a complaint of excessive sleepiness associated with a current diagnosis of:
  • Narcolepsy-Diagnosis made on the basis of International Classification of Sleep Disorders (ICSD) (American Sleep Disorders Association 2000) criteria.
  • OSAHS-Diagnosis made on the basis of ICSD criteria. Furthermore, patients with OSAHS must meet the following nCPAP therapy requirements:
  • Previous adequate education and intervention efforts to encourage nCPAP therapy use must be documented.
  • A patient's nCPAP therapy regimen must be stable for at least 4 weeks.
  • nCPAP therapy is effective, in the opinion of the investigator.
  • Evidence of regular nCPAP usage must be shown during a 2 week evaluation period (ie, nCPAP therapy usage of at least 4 hours/night on at least 70% of the nights).
  • Chronic SWSD-Diagnosis made on the basis of at least minimum ICSD criteria. Furthermore, patients with chronic SWSD must have had excessive sleepiness during night shifts for at least 3 months, work a minimum of 3 night shifts per month that include at least 6 hours between 2200 and 0800 and are no longer than 12 hours in duration, and plan to continue to work night shifts throughout the study.
  • The patient has a Clinical Global Impression of Severity of Disease (CGI-S) rating of 4 or more. (For patients with OSAHS, the CGI-S scale will be administered after nCPAP effectiveness and regular usage is established. For patients with narcolepsy or OSAHS, CGI-S will be evaluated to assess general clinical condition. For patients with SWSD, CGI-S will be evaluated to assess sleepiness during the night shift including the commute to and from work.)
  • The patient is in good health as determined by a medical and psychiatric history, medical examination, electrocardiogram (ECG), serum chemistry and hematology. Women must be surgically sterile, 2 years postmenopausal, or if of childbearing potential, must use a medically accepted method of birth control (ie, barrier method with spermicide, steroidal contraceptive \[oral, implanted, and Depo-Provera contraceptives must be used in conjunction with a barrier method\], or intrauterine device \[IUD\]).
  • The patient may have been prescribed PROVIGIL or stimulant therapy to treat the sleep disorder; however, they must have undergone a washout period of at least 7 days prior to screening assessments.
  • The patient must be willing and able to comply with study restrictions and to attend regularly scheduled clinic visits as specified in this protocol.

Критерии невключения

  • Patients are excluded from participating in this study if 1 or more of the following criteria are met:
  • have any clinically significant, uncontrolled medical conditions (treated or untreated)
  • have a probable diagnosis of a current sleep disorder other than the primary diagnosis of narcolepsy, OSAHS, or chronic SWSD
  • consume caffeine including coffee, tea and/or other caffeine containing beverages or food averaging more than 600 mg of caffeine or more than 8 cups of coffee per day
  • used any prescription drugs disallowed by the protocol or clinically significant use of over-the-counter (OTC) drugs within 7 days before the baseline visit
  • have a history of alcohol, narcotic, or any other drug abuse as defined by the Diagnostic and Statistical Manual of the American Psychiatric Association, 4th Edition (DSM IV)
  • have a positive UDS at the screening visit
  • have a clinically significant deviation from normal in the physical examination
  • are pregnant or lactating. Any woman becoming pregnant during the study will be withdrawn from the study
  • have used an investigational drug within 1 month before the screening visit
  • have any disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including gastrointestinal surgery)
  • have a known clinically significant drug sensitivity to stimulants

Источник: ClinicalTrials.gov, NCT00078312 · запись обновлена в реестре 19 июля 2013.

Дизайн и результаты

ДизайнНерандомизированное, открытое (без ослепления), одна группа; цель — лечение
Включено участников (факт, все страны)328
Что измеряют — первичные конечные точки (1)
  • Safety and Tolerability as Measured by Number of Participants With Adverse Events — Screening/Baseline and months 1, 3, 6, 9, and 12 and every 3 months thereafter

Цель исследования

The primary objective of this study is to evaluate the safety and tolerability of Armodafinil (CEP-10953) administered on a flexible-dosage regimen of 100 to 250 mg/day for up to 12 months to patients with excessive sleepiness associated with a current diagnosis of narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSAHS)(regular users of nasal continuous positive airway pressure \[nCPAP\] therapy), or chronic shift work sleep disorder (SWSD).

Где проходит

8 центров в 2 городах

Откуда эта информация

  • ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00078312 Официальный реестр (США) · загружено 9 ноября 2026
    Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор, центры

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.